Analysts estimate that Karyopharm Therapeutics will report an earnings per share (EPS) of $-3.86.
The announcement from Karyopharm Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's ...
Analysts estimate that Karyopharm Therapeutics will report an earnings per share (EPS) of $-3.86.
The announcement from Karyopharm Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Performance in Previous EarningsIn the previous earnings release, the company beat EPS by $0.32, leading to a 20.0% drop in the share price the following trading session.
Here's a look at Karyopharm Therapeutics's past performance and the resulting price change:
Quarter
Q1 2025
Q4 2024
Q3 2024
Q2 2024
EPS Estimate
-3.09
-4.05
-3.9
-4.5
EPS Actual
-2.77
-3.60
-3.9
-3
Price Change %
-20.0%
2.0%
5.0%
-3.0%
Stock PerformanceShares of Karyopharm Therapeutics were trading at $3.97 as of August 07. Over the last 52-week period, shares are down 67.44%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
To track all earnings releases for Karyopharm Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.